This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2015 Mar 3;84(9):864-5.

doi: 10.1212/WNL.0000000000001319. Epub 2015 Jan 30.

Multiple sclerosis, immunomodulation, and immunizations: balancing the benefits

Myla D Goldman¹, Robert T Naismith²

Affiliations

Affiliations

¹ From the Department of Neurology (M.D.G.), University of Virginia, Charlottesville; and the Department of Neurology (R.T.N.), Washington University, St. Louis, MO. mdg3n@virginia.edu.
² From the Department of Neurology (M.D.G.), University of Virginia, Charlottesville; and the Department of Neurology (R.T.N.), Washington University, St. Louis, MO.

PMID: 25636716
DOI: 10.1212/WNL.0000000000001319

Editorial

Multiple sclerosis, immunomodulation, and immunizations: balancing the benefits

Myla D Goldman et al. Neurology. 2015.

. 2015 Mar 3;84(9):864-5.

doi: 10.1212/WNL.0000000000001319. Epub 2015 Jan 30.

Authors

Myla D Goldman¹, Robert T Naismith²

Affiliations

¹ From the Department of Neurology (M.D.G.), University of Virginia, Charlottesville; and the Department of Neurology (R.T.N.), Washington University, St. Louis, MO. mdg3n@virginia.edu.
² From the Department of Neurology (M.D.G.), University of Virginia, Charlottesville; and the Department of Neurology (R.T.N.), Washington University, St. Louis, MO.

PMID: 25636716
DOI: 10.1212/WNL.0000000000001319

No abstract available

PubMed Disclaimer

Comment on

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis.
Kappos L, Mehling M, Arroyo R, Izquierdo G, Selmaj K, Curovic-Perisic V, Keil A, Bijarnia M, Singh A, von Rosenstiel P. Kappos L, et al. Neurology. 2015 Mar 3;84(9):872-9. doi: 10.1212/WNL.0000000000001302. Epub 2015 Jan 30. Neurology. 2015. PMID: 25636714 Clinical Trial.

Similar articles

ACP Journal Club. In multiple sclerosis, use of fingolimod reduced immune responses to influenza and tetanus booster vaccines.
Absher JR. Absher JR. Ann Intern Med. 2015 Jun 16;162(12):JC8. doi: 10.7326/ACPJC-2015-162-12-008. Ann Intern Med. 2015. PMID: 26075785 No abstract available.
New drugs may improve, complicate treatment for multiple sclerosis.
Link H, Martin R. Link H, et al. Nat Med. 2010 Mar;16(3):272. doi: 10.1038/nm0310-272. Nat Med. 2010. PMID: 20208513 No abstract available.
The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation.
Haghikia A, Gold R. Haghikia A, et al. Am J Pathol. 2010 Jun;176(6):2599-601. doi: 10.2353/ajpath.2010.100200. Epub 2010 Apr 15. Am J Pathol. 2010. PMID: 20395429 Free PMC article.
ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720).
Hopkins CR. Hopkins CR. ACS Chem Neurosci. 2011 Mar 16;2(3):116-7. doi: 10.1021/cn100113g. ACS Chem Neurosci. 2011. PMID: 22778861 Free PMC article. Review. No abstract available.
Fingolimod for multiple sclerosis.
Pelletier D, Hafler DA. Pelletier D, et al. N Engl J Med. 2012 Jan 26;366(4):339-47. doi: 10.1056/NEJMct1101691. N Engl J Med. 2012. PMID: 22276823 Review. No abstract available.

See all similar articles

Cited by

Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS.
Carvajal R, Guananga-Álvarez D, Tur C, Esperalba J, Rodríguez-Barranco M, Rando-Segura A, Borras-Bermejo B, Cobo-Calvo A, Carbonell-Mirabent P, Zules-Oña R, Rodrigo-Pendas JA, Martínez-Gómez X, Montalban X, Tintore M, Otero-Romero S. Carvajal R, et al. Neurology. 2025 Feb 11;104(3):e210281. doi: 10.1212/WNL.0000000000210281. Epub 2025 Jan 16. Neurology. 2025. PMID: 39819099 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information